Vinge advises Samhällsbyggnadsbolaget i Norden AB (publ) ("SBB") in connection with its sale of stake in its social infrastructure portfolio for public education to Brookfield for SEK 9.2 billion. The transaction also includes earn out payments up to SEK 1.2 billion.
The loan agreement with the European Investment Bank (EIB) grants Oncopeptides access to a renewed unsecured loan facility of up to EUR 30 million. The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company, inter alia, satisfies certain milestones related to the ongoing commercialization of Pepaxti® in Europe and a potential relaunch of Pepaxto® in the US. In connection with the loan agreement, Oncopeptides has entered into a renewed warrant agreement with the EIB, entitling the EIB to warrants in the company should the company draw on the loan facility.
Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of Holmströms Rör AB, Holmströms Rör i Ängelholm AB and Holmströms Rör Syd Väst AB.
Vinge has advised Luossavaara-Kiirunavaara AB (publ) (“LKAB”) in connection with its investment in, REEtec Holding AS (“REEtec”). LKAB invests in the financing round, that totals NOK 1.2 billion, to become the largest shareholder of REEtec.
Vinge has advised STARK Group in connection with its acquisition of the Nordic tiles actor FagFlis Group with its Swedish operation FF Kakel AB. The group has conducted operations since 1981 and includes, in addition to the Swedish stores, approximately 30 facilities in Norway with total turnover of approximately NOK 750 million.
Vinge has advised Baseload Capital Holding AB in connection with a financing round of approximately SEK 500 million. The financing consists of (i) the issuance of convertible debentures of USD 24 million to current and new investors and (ii) a convertible term facility of EUR 25 million from Sustainable Development Capital (SDCL) to finance development of current and future geothermal energy facilities.
Vinge advises EQT Infrastructure III and IV funds (“EQT Infrastructure”) in connection with their divestment of a minority stake in the GlobalConnect group (“GlobalConnect”) to Mubadala Investment Company (“Mubadala”). Having been invested in GlobalConnect since 2017, EQT Infrastructure will remain as the largest shareholder following the closing of the transaction.
Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of J. Gullikssons El Aktiebolag, Elkalkyl och Elprojektering i Sverige AB and Reglerab AB.
Vinge represents Altor Fund V in connection with its investment in H2 Green Steel. The investment has been carried out in connection with H2 Green Steel's series B round totalling approx. EUR 190 million. Investors participating in the capital raise included, in addition to Altor, inter alia AMF, GIC, Swedbank Robur Alternative Equity, FAM and IMAS Foundation.
The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 435,6 million, before issue costs. The price per share in the share issue corresponds to the closing price on Nasdaq Stockholm the day of the share issue.
